Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
Peritoneal mucinous carcinomatosis is an aggressive subtype of pseudomyxoma peritonei, which often leads to inoperable bowel obstruction and, ultimately, death. Due to the poor prognosis, treatment is often symptomatic and aimed at alleviating the symptoms - pain, nausea, and vomiting - associated w...
Main Authors: | Gema Marín Zafra, Pedro Segura Luque |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-01-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/433577 |
Similar Items
-
The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
by: Willem Lybaert
Published: (2014-01-01) -
Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
by: Daleen Geldenhuys, et al.
Published: (2020-10-01) -
Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel®: A Case Report
by: Willem Lybaert, et al.
Published: (2014-09-01) -
Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
by: Paragliola RM, et al.
Published: (2016-10-01) -
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
by: Zhenmei An, et al.
Published: (2020-05-01)